Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eton Pharmaceuticals (ETON) Cash from Operations (2019 - 2025)

Historic Cash from Operations for Eton Pharmaceuticals (ETON) over the last 7 years, with Q3 2025 value amounting to $12.0 million.

  • Eton Pharmaceuticals' Cash from Operations rose 30738.48% to $12.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $21.3 million, marking a year-over-year increase of 90471.48%. This contributed to the annual value of $969000.0 for FY2024, which is 8578.14% down from last year.
  • According to the latest figures from Q3 2025, Eton Pharmaceuticals' Cash from Operations is $12.0 million, which was up 30738.48% from $8.0 million recorded in Q2 2025.
  • In the past 5 years, Eton Pharmaceuticals' Cash from Operations ranged from a high of $12.0 million in Q3 2025 and a low of -$5.1 million during Q4 2021
  • Over the past 5 years, Eton Pharmaceuticals' median Cash from Operations value was $1.2 million (recorded in 2022), while the average stood at $1.6 million.
  • In the last 5 years, Eton Pharmaceuticals' Cash from Operations soared by 76693.77% in 2022 and then tumbled by 29767.44% in 2024.
  • Over the past 5 years, Eton Pharmaceuticals' Cash from Operations (Quarter) stood at -$5.1 million in 2021, then soared by 155.5% to $2.8 million in 2022, then crashed by 86.37% to $387000.0 in 2023, then plummeted by 297.67% to -$765000.0 in 2024, then skyrocketed by 1672.03% to $12.0 million in 2025.
  • Its Cash from Operations stands at $12.0 million for Q3 2025, versus $8.0 million for Q2 2025 and $2.1 million for Q1 2025.